Media Inquiries

If you are a credentialed member of the media, please submit a request via this link: Request For Comment | HHS.gov. If you are a scientist who has been contacted by a member of the media, please refer them to the link above.

Our Discoveries

Immunofluorescence image of the cell adhesion protein basigin (turquoise) in TuNEPs released from dying 4T1 mouse breast cancer cells.

Proteins Released from the Nuclei of Dying Cancer Cells Promote Tumor Growth

Material released from dying cancer cells, known as tumor cell nuclear expulsion products (TuNEPs), contains specific proteins that promote the growth of neighboring cancer cells. Targeting these proteins could lead to new treatments that hinder cancer spread and improve patient outcomes.

Read More

An illustration of papillomas in the throat

CCR Research Leads to FDA Approval of First Immunotherapy for Recurrent Respiratory Papillomatosis

The U.S. Food and Drug Administration has granted full market approval for Papzimeos (zopapogene imadenovec-drba), a groundbreaking non-replicating adenoviral vector-based immunotherapy designed for adult patients with recurrent respiratory papillomatosis (RRP).

Read More

a small cluster of cancer cells that has spread from the primary tumor

Protein makes cancer cells easier to destroy with immunotherapy

A protein called GCN1 can trigger a stress response inside cancer cells and simultaneously help them hide from the immune system. Research found these processes can be blocked by another protein called IMPACT, which could enhance immunotherapy’s ability to find and kill cancer cells.

Read More

Spatial heatmap of CD3+ T cells in small cell lung cancer (SCLC) tumors. Top: Notch1 gene inactive, “cold” SCLC with T cells located on the tumor periphery (immune-excluded). Bottom: Notch1 gene active, “hot” SCLC with abundant T cell tumor infiltration (immune-inflamed).

Activated gene elicits robust immune response in lung cancer

The activation of NOTCH1, a gene known to control cell differentiation and growth, stimulates a robust immune response in small cell lung cancer. Expression of this gene can also predict survival with immunotherapy.

Read More

Cells showing the biosensor used in this study to test the activity of APC/C

Study uncovers new details on pulsing enzyme activity during cell cycle

Enzymatic activity during the start of the cell cycle could be harnessed to inhibit cancer cell reproduction.

Read More

An illustration of immune cells with zeroes and ones, representing CIDE, a new, large-scale immuno-oncology data platform.

Cancer Immunology Data Engine uncovers secreted proteins with therapeutic potential

CCR researchers have developed a new tool that identifies secreted proteins associated with immunotherapy outcomes.

Read More

Graphic depiction of near-infrared photoimmunotherapy (NIR-PIT) targeted against ICAM-1 markers (small, blue, Y-shaped), causing cancer cell death and suppressed tumor growth (pink cluster, center).

CCR-developed cancer therapy shrinks tumors and boosts immune response

A targeted cancer therapy developed at CCR shows promise in its ability to target a common cancer cell marker, both shrinking tumors and producing a boosted immune response.

Read More

A graphic depiction of the dimethoxyphenyl cyanoacrylamide (DiMe) chemical warhead facilitating reversible binding of drug to its molecular target.

Synthesized chemical component helps cancer drugs remain stable in water

Researchers developed a new chemical component that can be attached to drug molecules to make them more stable in water without losing effectiveness. This innovation could improve the performance of some cancer treatments.

Read More

Micrograph of renal cell carcinoma.

Combining bevacizumab with erlotinib shrinks tumors in patients with rare and aggressive kidney cancer

Seventy-two percent of patients with HLRCC-associated kidney cancers, for which there previously was no known drug treatment, responded to the therapy in a clinical trial.

Read More

Acute myeloid leukemia. Image credit: iStock

Researchers uncover why a leukemia treatment can cause problems with movement and balance

Ara-C, also known as cytarabine, is the most common chemotherapy to cause cerebellar toxicity. Researchers discovered how the treatment leaves certain neurons with double-strand breaks in their DNA.

Read More